Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

66 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
A study of vaccine-induced immune pressure on breakthrough infections in the Phambili phase 2b HIV-1 vaccine efficacy trial.
Hertz T, Logan MG, Rolland M, Magaret CA, Rademeyer C, Fiore-Gartland A, Edlefsen PT, DeCamp A, Ahmed H, Ngandu N, Larsen BB, Frahm N, Marais J, Thebus R, Geraghty D, Hural J, Corey L, Kublin J, Gray G, McElrath MJ, Mullins JI, Gilbert PB, Williamson C. Hertz T, et al. Among authors: ngandu n. Vaccine. 2016 Nov 11;34(47):5792-5801. doi: 10.1016/j.vaccine.2016.09.054. Epub 2016 Oct 15. Vaccine. 2016. PMID: 27756485 Free PMC article. Clinical Trial.
Temporal association of HLA-B*81:01- and HLA-B*39:10-mediated HIV-1 p24 sequence evolution with disease progression.
Ntale RS, Chopera DR, Ngandu NK, Assis de Rosa D, Zembe L, Gamieldien H, Mlotshwa M, Werner L, Woodman Z, Mlisana K, Abdool Karim S, Gray CM, Williamson C; CAPRISA 002 Study Team. Ntale RS, et al. Among authors: ngandu nk. J Virol. 2012 Nov;86(22):12013-24. doi: 10.1128/JVI.00539-12. Epub 2012 Aug 29. J Virol. 2012. PMID: 22933291 Free PMC article.
Intersubtype differences in the effect of a rare p24 gag mutation on HIV-1 replicative fitness.
Chopera DR, Cotton LA, Zawaira A, Mann JK, Ngandu NK, Ntale R, Carlson JM, Mlisana K, Woodman Z, de Assis Rosa D, Martin E, Miura T, Pereyra F, Walker BD, Gray CM, Martin DP, Ndung'u T, Brockman MA, Karim SA, Brumme ZL, Williamson C; CAPRISA 002 Study Team. Chopera DR, et al. J Virol. 2012 Dec;86(24):13423-33. doi: 10.1128/JVI.02171-12. Epub 2012 Sep 26. J Virol. 2012. PMID: 23015721 Free PMC article.
Evolution of an HIV glycan-dependent broadly neutralizing antibody epitope through immune escape.
Moore PL, Gray ES, Wibmer CK, Bhiman JN, Nonyane M, Sheward DJ, Hermanus T, Bajimaya S, Tumba NL, Abrahams MR, Lambson BE, Ranchobe N, Ping L, Ngandu N, Abdool Karim Q, Abdool Karim SS, Swanstrom RI, Seaman MS, Williamson C, Morris L. Moore PL, et al. Among authors: ngandu n. Nat Med. 2012 Nov;18(11):1688-92. doi: 10.1038/nm.2985. Epub 2012 Oct 21. Nat Med. 2012. PMID: 23086475 Free PMC article.
Identification of broadly neutralizing antibody epitopes in the HIV-1 envelope glycoprotein using evolutionary models.
Lacerda M, Moore PL, Ngandu NK, Seaman M, Gray ES, Murrell B, Krishnamoorthy M, Nonyane M, Madiga M, Wibmer CK, Sheward D, Bailer RT, Gao H, Greene KM, Karim SS, Mascola JR, Korber BT, Montefiori DC, Morris L, Williamson C, Seoighe C; CAVD-NSDP Consortium. Lacerda M, et al. Virol J. 2013 Dec 2;10:347. doi: 10.1186/1743-422X-10-347. Virol J. 2013. PMID: 24295501 Free PMC article.
Safety and pharmacokinetics of subcutaneous administration of broadly neutralizing anti-HIV-1 monoclonal antibodies (bNAbs), given to HIV-1 exposed, uninfected neonates and infants: study protocol for a phase I trial.
Goga A, Ramraj T, Naidoo L, Daniels B, Matlou M, Chetty T, Dassaye R, Ngandu NK, Galli L, Reddy T, Seocharan I, Ndlangamandla Q, September Q, Ngcobo N, Reddy M, Cafun-Naidoo T, Woeber K, Jeenarain N, Imamdin R, Maharajh K, Ramjeth A, Bhengu T, Clarence E, Van de Perre P, Tylleskär T, Nagot N, Moles JP, Moore PL, Mkhize NN, Gama L, Dispinseri S, Biswas P, Scarlatti G; PedMAb1 clinical trial team. Goga A, et al. Among authors: ngandu nk. BMC Infect Dis. 2024 Jul 20;24(1):712. doi: 10.1186/s12879-024-09588-3. BMC Infect Dis. 2024. PMID: 39033300 Free PMC article.
Human immunodeficiency virus-specific gamma interferon enzyme-linked immunospot assay responses targeting specific regions of the proteome during primary subtype C infection are poor predictors of the course of viremia and set point.
Gray CM, Mlotshwa M, Riou C, Mathebula T, de Assis Rosa D, Mashishi T, Seoighe C, Ngandu N, van Loggerenberg F, Morris L, Mlisana K, Williamson C, Karim SA; CAPRISA 002 Acute Infection Study Team. Gray CM, et al. Among authors: ngandu n. J Virol. 2009 Jan;83(1):470-8. doi: 10.1128/JVI.01678-08. Epub 2008 Oct 22. J Virol. 2009. PMID: 18945774 Free PMC article.
66 results